Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating expenses:
Research and development	$ 500,173	$ 503,551
Clinical and regulatory	3,157,835	2,169,473
General and administrative	1,031,158	1,309,156
Total operating expenses	4,689,166	3,982,180
Loss from operations	(4,689,166)	(3,982,180)
Non-operating income (expenses)
Interest income	11,101	9,126
Other income	79,701	21,617
Interest expense	(136,122)	(75,430)
Total non-operating expenses, net	(45,320)	(44,687)
Net loss	(4,734,486)	(4,026,867)
Net loss - non-controlling interest	(174,883)	(117,669)
Net loss attributable to Heat Biologics, Inc.	$ (4,559,603)	$ (3,909,198)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted	$ (0.50)	$ (0.57)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc. - basic and diluted	9,124,641	6,814,863
Net loss	$ (4,734,486)	$ (4,026,867)
Other comprehensive loss:
Unrealized loss on foreign currency translation	(75,807)	(20,865)
Total other comprehensive loss	(4,810,293)	(4,047,732)
Comprehensive loss attributable to non-controlling interest	(174,883)	(117,669)
Comprehensive loss attributable to Heat Biologics, Inc.	$ (4,635,410)	$ (3,930,063)